This study further investigated the impact
of nicotine use / smoking
status and variation in the mu opioid receptor
gene (OPRM1), specifically, an A118G
single nucleotide polymorphism (SNP, or DNA sequence variation), on the effects
of naltrexone on a range
of drinking outcomes.
No
single non-synonymous (NS)
single nucleotide variant (SNV) nor any
gene carrying a higher burden
of NS SNVs was significantly associated with PD
status after multiple - testing correction.